AQR Capital Management LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

AQR Capital Management LLC lowered its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 36.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 386,177 shares of the biotechnology company’s stock after selling 226,028 shares during the quarter. AQR Capital Management LLC owned 0.54% of Aclaris Therapeutics worth $425,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ACRS. SG Americas Securities LLC boosted its stake in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after buying an additional 13,461 shares during the period. BNP Paribas Financial Markets raised its position in shares of Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Aclaris Therapeutics during the first quarter valued at approximately $39,000. Russell Investments Group Ltd. increased its position in Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 61,602 shares during the last quarter. Finally, Deuterium Capital Management LLC acquired a new stake in Aclaris Therapeutics during the 1st quarter worth approximately $99,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Trading Down 1.7 %

Shares of Aclaris Therapeutics stock opened at $1.18 on Wednesday. Aclaris Therapeutics, Inc. has a 1 year low of $0.59 and a 1 year high of $5.71. The company has a market cap of $84.09 million, a price-to-earnings ratio of -1.08 and a beta of 0.20. The company’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.20.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The company had revenue of $2.77 million for the quarter, compared to the consensus estimate of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. As a group, research analysts forecast that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ACRS. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th. Seven research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Insider Activity

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard acquired 130,317 shares of Aclaris Therapeutics stock in a transaction on Thursday, July 18th. The shares were purchased at an average cost of $1.30 per share, with a total value of $169,412.10. Following the completion of the purchase, the insider now owns 13,578,286 shares in the company, valued at $17,651,771.80. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 321,763 shares of company stock valued at $418,823 over the last 90 days. 6.40% of the stock is owned by company insiders.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.